**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 28112**

**Manuscript Type: Minireviews**

**Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma**

Yang PC *et al*. Prophylactic liver transplant for high-risk recurrent HCC

**Po-Chih Yang, Cheng-Maw Ho, Rey-Heng Hu, Ming-Chih Ho, Yao-Ming Wu, Po-Huang Lee**

**Po-Chih Yang**, Department of Surgery, National Taiwan University Hospital Hsinchu Branch, Hsinchu City 300, Taiwan

**Cheng-Maw Ho**, **Rey-Heng Hu, Ming-Chih Ho, Yao-Ming Wu, Po-Huang Lee,** Department of Surgery, National Taiwan University Hospital, Taipei 10002, Taiwan

**Author contributions:** Yang PC performed the majority of the writing, prepared the figures and tables; Hu RH and Ho MC performed data accusation and writing; Wu YM provided the input in writing the paper; Lee PH assisted with the design and interpretation of this study; Ho CM designed the outline and coordinated the writing of the paper.

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the senior authors or other coauthors who contributed to this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence: Cheng-Maw Ho**, **MD, PhD, Clinical Assistant Professor,** Department of Surgery, National Taiwan University Hospital, 7 Chung-Shan S. Rd., Taipei 10002, Taiwan. miningho@ntu.edu.tw

**Telephone**: +886-2-23123456

**Fax**: +886-2-23568810

**Received:** June 27, 2016

**Peer-review started:** June 27, 2016

**First decision:** August 18, 2016

**Revised:** August 24, 2016

**Accepted:** September 13, 2016

**Article in press:**

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in the world. Radical treatment of HCC in early stages results in a long disease-free period and improved overall survival. The choice of optimal management strategy for HCC mainly depends on the severity of the underlying liver disease. For patients with decompensated liver cirrhosis and HCC within Milan criteria (MC), liver transplant (LT) is the choice of treatment. However, for patients with good residual liver reserve and HCC within MC, selection of other curative treatments such as liver resection (LR) or radiofrequency ablation may be a reasonable alternative. For patients without cirrhosis, LR can result in an overall survival similar to that provided by LT. Therefore, it is an accepted alternative to LT especially in areas with organ shortage. However, the cumulative 5-year recurrence rate of HCC post LR might be as high as 70%. For initial transplant-eligible (within MC) patients with recurrent HCC post LR, salvage liver transplant (SLT) was first proposed in 2000. However, most patients with recurrent HCC considered for SLT are untransplantable cases due to HCC recurrence beyond MC or comorbidity. Thus, the strategy of opting for SLT results in the loss of the opportunity of LT for these patients. Some authors proposed the concept of “de principe liver transplant” (*i.e.*, prophylactic LT before HCC recurrence) to prevent losing the chance of LT for these potential candidates. Factors associated with the failure of SLT will be dissected and discussed in three parts: patient, tumor, and underlying liver disease. Regarding patient-related factors, the rate of transplantability depends on patient compliance. Patients without regular follow-up tend to develop HCC recurrence beyond MC at the time of tumor detection. Advancing age is another factor related to severe comorbidities when LT is considered for HCC recurrence, and these elderly candidates become ineligible as time goes by. Regarding tumor-related factors, histopathological features of the resected specimen are used mostly for determining the prognosis of early HCC recurrences. Such prognostic factors include the presence of microvascular invasion, poor tumor differentiation, the presence of microsatellites, the presence of multiple tumors, and the presence of the gene-expressing signature associated with aggressive HCC. These prognostic factors might be used as a selection tool for SLT or prophylactic LT, while remaining mindful of the fact that most of them are also prognostic factors for post-transplant HCC recurrence. Regarding underlying liver disease-related factors, progression of chronic viral hepatitis and high viral load may contribute to the development of late (de novo) HCC recurrence as a consequence of sustained inflammatory reaction. However, correlation between the severity of liver fibrosis and tumor recurrence is still controversial. Some prognostic scoring systems that integrate these three factors have been proposed to predict recurrence patterns after LR for HCC. Theoretically, after excluding patients with high risk of post-transplant HCC recurrence, either by observation of a cancer-free period or by measurement of biological factors (such as alpha fetoprotein), prophylactic LT following curative resection of HCC could be considered for selected patients with high risk of recurrence to provide longer survival.

**Key words:** Liver transplant; Hepatocellular carcinoma; Salvage; Prophylactic; Recurrence; Risk factor; Resection; Microvascular invasion

© **The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this minireview, we discuss about the strategy of prophylactic liver transplant after liver resection for patients with a high risk of recurrence. Prognostic risk factors and scoring systems for recurrence are also analyzed.

Yang PC, Ho CM, Hu RH, Ho MC, Wu YM, Lee PH. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. *World J Hepatol* 2016; In press

**Introduction**

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It has a high prevalence in Asia and sub-Saharan Africa due to the high incidence of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in these regions. It is much more common in men than in women. In men, HCC is the second leading cause of cancer-related death in developing countries and worldwide[1].

It is well established that liver transplant (LT) is the treatment of choice for patients with early HCC and decompensated liver disease[2].The most notable criteria for transplant in HCC cases is the Milan criteria (MC) described by Mazzafero *et al*[3] in 1996. In selected patients with a single tumor less than 5 cm in diameter, or no more than 3 tumors each 3 cm or less in diameter, LT can offer a > 70% 5-year survival and a < 10% 5-year recurrence rate[4]. However, for patients with early HCC and cirrhotic liver with preserved function, the choice between LR and LT has been an issue of debate[5]. Donor organ shortage is the major problem with using LT for this group of patients[6]. Primary LR can achieve comparable 5-year overall survival rates (> 70%) with proper patient selection and application of advanced surgical techniques over the last decades[7-10]. However, the intrahepatic recurrence rate within 5 years of LR in cirrhotic patients is > 70%[11]. In the era of organ shortage, Majno *et al*[12] first proposed a treatment strategy that involves performing LR as the first-line treatment for patients with single small HCC and preserved liver function and reserving LT for patients with recurrent HCC within MC.This is the so-called “salvage liver transplant (SLT)” strategy. Most patients with HCC recurrence cannot benefit by this strategy in the real-world clinical setting due to recurrent HCC beyond MC at detection or poor general condition unsuitable for LT. We speculate whether early LT before the development of untransplantable recurrence can save their lives and eradicate the cancer. This concept of prophylactic LT for high-risk recurrent HCC before the development of recurrence is also called “de principe liver transplant”[13].Recently, some authors suggested the use of the histopathological features of the specimen of the resected tumor as the selection tool for LT to improve the outcome of cases with high recurrence rate after LR[13-16]. However, most of these histopathological features are also prognostic factors of post-transplant HCC recurrence. This review will discuss the treatment strategy of LT before HCC recurrence (de principe) and at recurrence (salvage) for initial transplant-eligible patients developing recurrent tumors after LR. Poor prognostic clinicopathological factors associated with early and late HCC recurrence are also reviewed in three parts, “patient,” ”tumor,” and ”underlying liver disease.” At last, we introduce some scoring systems for predicting HCC recurrence after LR.

**Liver transplant at HCC recurrence: Salvage liver transplant**

LR as the first-line treatment for primary small HCC in compensated cirrhotic liver is widely adopted with an acceptable survival rate but a high recurrence rate. No treatment guidelines exist for recurrent HCC after LR. Salvage curative treatment for recurrent HCC following primary LR includes SLT, repeat LR, and radiofrequency ablation (RFA). In our group, Lee *et al*[17] first reported in 1995 that the cumulative 5-year survival rates in patients undergoing repeated hepatic resection after the first operation was 65.1%, and according to Ho *et al*[18],the latest 5-year survival rates after recurrence in patients receiving repeat hepatectomy was 72%, which is similar to that of patients who have undergone primary resection and have no recurrence. Chan *et al*[19] report comparable survival rates and tumor-free survival rates in SLT and repeat LR, but RFA yields poorer outcome than SLT and repeat LR (5-year survival rates in SLT, repeat LR, and RFA: 50.0%, 48.0%, 11.4%, respectively; 5-year tumor-free survival rates in SLT, repeat LR, and RFA: 57.9%, 49.3%, 10.6%, respectively).RFA is associated with poor survival rates but can be considered for patients not suitable for LR. In another series by Yamashita *et al*[20] which compared the outcomes between repeat LR and SLT, the perioperative outcomes including the operation time, intraoperative blood loss, the length of hospital stay, and post-operative morbidity, were all significant worse in the SLT group. No significant difference was observed in the overall survival between these two groups, but patients who underwent SLT had better disease-free survival[20,21]. The difference between the results of these two salvage treatments is similar to the difference between primary LT and initial LR for early HCC in compensated liver. However, in areas without sufficient donors, repeat LR is the only treatment for patients with recurrent HCC and enough remnant liver that can provide an overall survival comparable to SLT. Mise *et al*[22] report the result of third or more repeat hepatectomies for recurrent HCC. The 5- and 10-year overall survival rates from the initial hepatectomy are 91.4% and 75.5% respectively, and the 5-year disease-free survival rate after the second hepatectomy is 17.9%.

Comparison of primary LT and SLT for HCC within MC in recent studies revealed similar perioperative course, morbidity, overall survival, and disease-free survival[16,23-28], while a previous study showed the association of LT after resection and higher operative mortality, an increase of recurrence, and poorer outcomes[29]. In the systemic review by Chan *et al*[30] the median 5-year overall and disease-free survival rates in SLT are 62% and 67%, respectively.In the era of organ shortage, LR should be considered as the primary curative treatment for resectable tumors in compensated livers, and SLT is a safe and effective strategy for initial transplant-eligible patients when recurrent HCC or hepatic function deterioration occur[12].

The SLT strategy is widely acceptable for patients with previous transplant-eligible HCC. However, some authors also advocate the strategy of performing LR as one of the locoregional therapies for tumor downstaging in patients with initial HCC beyond LT criteria and performing LT after HCC recurrence[31]. The results of this downstaging strategy showed better survival outcomes as compared with patients with HCC recurrence who undergo LR without SLT. However, for post-LR recurrent HCC beyond MC, the results of SLT are not beneficial and not recommended in a recent report[22].Prospective studies are needed to examine the long-term outcomes of extending the criteria of LT for intermediate-advanced HCC either before or after tumor recurrence.

**Liver transplant before recurrence: COncept of Prophylactic liver transplant**

As previous study stated, SLT has been proven effective for patients with recurrent HCC within the criteria of the following: tumor recurrence within MC, patient adherence to a regular follow-up with imaging to detect early recurrence, and good general patient condition for LT. However, the intention-to-treat analysis by Fuks *et al*[32] showed that nearly half of the patients with recurrent HCC following LR did not undergo LT, including one-third due to recurrence beyond MC. Other studies also report that 20% to 80% of the patients considered for SLT are not transplantable due to recurrence beyond transplant criteria or advanced age with significant comorbidity[8,15,29,33,34]. This means that with the strategy of SLT, we lose the chance of LT in originally transplantable patient. Sala *et al*[13] first reported four cases of prophylactic LT, performed based on the expectation of early recurrence according to the gross and microscopic features of the resected specimen, including microvascular invasion and additional nodules.Patients with high risk of recurrence as identified by histopathological findings were enlisted for liver transplant. Scatton *et al*[14] predicted the risk of HCC recurrence after LR on the basis of the histological features of the resected specimen (including Edmondson score, vascular invasion, nuclear grade, and architectural growth pattern), which are used as the selection tool for LT. In this series, six patients were enlisted and underwent prophylactic LT without evidence of residual disease. However, the population of this study was heterogeneous, with three of the six patients in this study having HCC beyond MC at resection, and the other three patients having resected HCC within MC. These six patents are all alive without recurrence with mean follow-up of 55 mo.

Tribillon *et al*[34] report the largest series of prophylactic LT in intention-to-treat analysis of 63 patients with intermediate or bad pathological factors (microvascular invasion and/or moderate/poor differentiation) in the resected specimen being enlisted for LT prior to recurrence (de principe group). The overall survival of this group was compared to 48 patients with favorable pathological features being enlisted for LT at the time of HCC recurrence (salvage group). The 5-year survival rate since primary LR was significantly better in the de principe group as compared with the salvage group (84.6% *vs* 74.8%), and the 5-year disease survival rate was also better in the de principe group (79.3% *vs* 72.3%).

This active attitude of enlisting patients for LT prior to recurrence can treat both potential recurrent HCC and underlying liver disease. However, literature about this strategy is scarce. The most important viewpoint discussed in the literature about this prophylactic strategy is preventing original transplant-eligible patients from developing beyond MC at recurrence and provide longer survival. However, if more stringent follow-ups and increased accuracy of imaging studies lead to early detection of recurrent tumor for these patients, does the result still justify this novel strategy? Salvage treatment after detection of recurrent HCC includes LT, repeat hepatectomy, radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), sorafenib, and trans-arterial radiorembolization (Yttrium-90). The choice of these salvage treatment depends on the extent of underlying liver disease, the aggressiveness of tumor at recurrence, and the general condition of the patient. LT has been proven to be correlated with better overall survival and disease-free survival rates with careful patient selection as a curative method, as compared with other salvage treatments previously stated [17-19]. However, for cases without evidence of recurrence, it is unclear if we should choose prophylactic LT for patients with a high risk of recurrence or just close follow-ups and salvage treatment at recurrence. The accompanying morbidity and mortality with prophylactic LT and the limited number of organs also hinder this aggressive strategy. The comparison of the benefits and risks between prophylactic LT and the wait-and-see strategy followed by salvage treatment is listed in Table 1.

On the other hand, is a higher probability of recurrence after initial hepatectomy equivalent to a shorter disease-free survival after salvage or prophylactic LT? If HCC recurs easily after salvage or prophylactic LT, this strategy became meaningless. Most prognostic factors associated with recurrence after LR are also relevant to post-transplant recurrence, including microvascular invasion of HCC, larger tumor size, higher tumor number, poorer differentiation of the tumor, and higher level of alpha-fetoprotein (AFP)[35-37] (Table 2). It is difficult to distinguish patients with higher recurrence after hepatectomy from those with possible post-transplant HCC recurrence. A period of observation should be considered after primary LR to identify the aggressiveness of occult HCC in the absence of specific predicting factors. Further investigation is needed to stratify patients for better application of treatment after hepatectomy.

**Clinicopathological factors associated with high-risk recurrence**

The most important issue in adopting prophylactic LT is the identification of prognostic factors associated with high-risk recurrence. Tumor dissemination from primary tumor before resection and new lesion development in underlying oncogenic cirrhotic parenchyma are two major pathways leading to recurrence[38-42].The former is associated with early recurrence within 2 years after primary resection, while the latter is more likely associated with late recurrence[42-45].We summarize the recent data in the literature on the clinicopathological factors linked with HCC recurrence.

**Patient-RELATED factorS: demographic and biochemical factors**

The age factor associated with recurrence after resection remains controversial. Older age at resection may be suggestive of long-standing chronic liver disease and higher susceptibility to HCC recurrence over time. Older age (65 years or more) is an independent risk factor for tumor recurrence, as shown in the recent major series by Fan *et al*[46] and Pompili *et al*[47]. However, in the series of HBV-related HCC by Mathews *et al*[48] younger age (40 years or less) was closely associated with more aggressive disease and shorter disease-free survival after resection.The other major series by Hung *et al*[49] does not show old age (60 years or more) to be a poor independent factor for tumor recurrence.

Serum AFP level has been conventionally used as a simple and effective tool for routine surveillance of HCC and for monitoring recurrence following treatment[50]. Elevated serum AFP level at the time of resection has been frequently reported to predict the risk of post-resection recurrence of HCC[51-56]. Many studies have proposed the relationship between the pretreatment AFP level and tumor-free survival using different cut-off values of AFP level (for example, 20, 100, 400, or 1000 ng/mL)[44,49,57.58]. Higher pretreatment serum AFP level is associated with shorter disease-free period. Ho *et al*[51] proposed the value of 400 ng/mL as the cut-off AFP level to predict untransplantable recurrence after primary curative resection of HCC. However, in another study by Shim *et al*[59] the result of a test based on propensity score, included 525 patients who underwent HCC resection and showed no correlation between preoperative serum AFP level and the risk of recurrence. Serum AFP level can also be abnormally high in chronic hepatitis C and advanced cirrhotic liver without HCC[60]. It is controversial to use serum AFP level as the predictor of HCC recurrence. Instead of predicting the risk of recurrence, the higher level of serum AFP should be considered as the consequence of aggressive tumor features such as microvascular invasion and poorer tumor differentiation, which indicate worse prognosis[61]. Serum AFP level > 1000 ng/mL is also reported to be associated with higher post-transplant recurrence due to the correlation with more aggressive tumor biology[35-37].

**Tumor-RELATED factorS: histopathological factors**

It is well known that early recurrence after HCC resection is related to tumor dissemination prior to operation[42]. The histopathological profile obtained from the resected specimen has been used to predict the risk of tumor dissemination and as an objective selection tool for LT in the last decade[13,14,32,34]. Among these factors, microvascular invasion of the tumor is the most critical factor in disease dissemination. As seen in most cancers, angiogenesis, or new vessel formation, is essential for HCC growth[62].In advanced stages of tumor progression, HCC cells develop the ability to invade adjacent blood vessels and potentially begin to metastasize. The presence of microvascular invasion is the hallmark of aggressive tumor behavior and associated with high recurrence rate after curative resection[63]. *Sumie et al*[64] report 3-year recurrence-free survival rates in HCC with and without microvascular invasion to be 27.7% and 67.5%, respectively. Other poor histopathological features, like the presence of satellite nodules and poor tumor differentiation, are also recognized, along with microvascular invasion, to predict early recurrence[32,39,43,65-68]. Most of these poor histopathological factors associated with early recurrence after LR are also predictors of recurrence after LT, including larger tumor size, larger tumor number, satellite nodules, poorer tumor differentiation, and microvascular invasion (Table 2). These features are linked to the aggressiveness of the tumor biology and predict the recurrence both after LR and LT. Patients with a tendency of post-LR recurrence may also develop a risk of post-LT recurrence. While considering prophylactic LT for patients with these poor histopathological features, cut-off criteria should be made to exclude those with more aggressive HCC and also potentially easy recurrence after LT.

**Underlying liver disease-RELATED FACTORS: virological factors**

The preneoplastic status of underlying liver disease is considered to relate with elevated carcinogenesis and de novo tumor development in late phase recurrence (2 years after resection)[42]. The correlation between stage of liver fibrosis and disease-free survival is controversial. Grazi *et al.*[69] and Taura *et al*[70] showed that HCC without cirrhosis has better disease-free survival compared with HCC with cirrhosis after curative resection in Asia, while Beard *et al*[71] showed the reverse results for western countries. Instead of the severity of liver cirrhosis, the sustained necroinflammatory reaction resulting from higher hepatitis activity may play a more important role in the development of secondary primary HCC two years after resection. Initial high HBV viral loads > 2000 IU/mL[72] or 106 copies/mL[45] at the time of HBV-related HCC resection or one month post resection HBV DNA > 20000 IU/mL[49] are all proven to be independent risk factors for tumor recurrence. Ongoing HBV replication can induce active hepatitis and subsequent inflammation in oncogenic liver parenchyma leading to de novo recurrent HCC. Regarding Hepatitis C, patients with HCV infection tend to have higher hepatitis activity, which is related to elevated carcinogenesis, than patients with HBV infection[42]. However, the difference in recurrence-free survival is not significant between patients with HBV infection or those with HCV infection[73,74]. A recent national study of 11,950 patients in Japan by Utsunomiya *et al*[75] showed that patients without viral hepatitis have a significant lower risk of HCC recurrence than those with HBV or HCV infection.

**Scoring system**

Some authors propose the scoring system that integrated clinical, biochemical, and histopathological factors to classify the risk of HCC recurrence after resection[32,66,68,76] (Table 3). Most scoring systems consist of the extent of tumor invasiveness, while the Glasgow prognostic score originally used in the prediction of outcomes among non-small-cell lung cancer patients[77] is composed of the serum levels of C-reactive protein (CRP) and albumin. The higher serum level of CRP and lower serum level of albumin present in the systemic inflammatory response is associated with a more active viral hepatitis in the remnant liver parenchyma[76]. The higher scores in each system indicate shorter disease-free period and poorer outcome. The clinical risk score system by Lee *et al.*[68] uses pathological factors to predict the likelihood of recurrence after LR, and it can be used to identify patients who may lose the chance of SLT at recurrence. Whether this strategy system applies to prophylactic liver transplantation needs further validation.

**Conclusion**

Prophylactic liver transplant is a novel concept for patients with high-risk recurrent HCC after primary resection before recurrence. Microvascular invasion, larger tumor size, larger tumor number, and poor tumor differentiation are all predictors for recurrence after LR and LT, while serum AFP level > 1000 ng/mL is the unique feature for predicting recurrence after LT. The length of observation after prophylactic LT should be established to examine the occult aggressiveness of the HCC resulting in recurrence after LT. It is safe and effective when patients who fulfilled MC at the time of resection are carefully selected. Large prospective studies are required to clarify the long-term results of this strategy.

**References**

1 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]

2 **Mor E**, Tur-Kaspa R, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. *Ann Intern Med* 1998; **129**: 643-653 [PMID: 9786813 DOI: 10.7326/0003-4819-129-8-199810150-00013]

3 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]

4 **Mazzaferro V**, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009; **10**: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]

5 **Poon RT**. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection? *Ann Surg Oncol* 2007; **14**: 541-547 [PMID: 17103069 DOI: 10.1245/s10434-006-9156-z]

6 **Yamamoto J**, Iwatsuki S, Kosuge T, Dvorchik I, Shimada K, Marsh JW, Yamasaki S, Starzl TE. Should hepatomas be treated with hepatic resection or transplantation? *Cancer* 1999; **86**: 1151-1158 [PMID: 10506698 DOI: 10.1002/(SICI)1097-0142(19991001)86]

7 **Fan ST**, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. *Ann Surg* 2011; **253**: 745-758 [PMID: 21475015 DOI: 10.1097/SLA.0b013e3182111195]

8 **Poon RT**, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. *Ann Surg* 2002; **235**: 373-382 [PMID: 11882759 DOI: 10.1097/00000658-200203000-00009]

9 **Ho CM**, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. *Ann Surg Oncol* 2012; **19**: 826-833 [PMID: 21879276 DOI: 10.1245/s10434-011-1975-x]

10 **Yamashita Y**, Tsuijita E, Takeishi K, Ishida T, Ikegami T, Ezaki T, Maeda T, Utsunomiya T, Nagasue N, Shirabe K, Maehara Y. Trends in surgical results of hepatic resection for hepatocellular carcinoma: 1,000 consecutive cases over 20 years in a single institution. *Am J Surg* 2014; **207**: 890-896 [PMID: 24144344 DOI: 10.1016/j.amjsurg.2013.07.028]

11 **Forner A**, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]

12 **Majno PE**, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. *Hepatology* 2000; **31**: 899-906 [PMID: 10733546 DOI: 10.1053/he.2000.5763]

13 **Sala M**, Fuster J, Llovet JM, Navasa M, Solé M, Varela M, Pons F, Rimola A, García-Valdecasas JC, Brú C, Bruix J. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. *Liver Transpl* 2004; **10**: 1294-1300 [PMID: 15376311 DOI: 10.1002/lt.20202]

14 **Scatton O**, Zalinski S, Terris B, Lefevre JH, Casali A, Massault PP, Conti F, Calmus Y, Soubrane O. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. *Liver Transpl* 2008; **14**: 779-788 [PMID: 18508370 DOI: 10.1002/lt.21431]

15 **Cherqui D**, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. *Ann Surg* 2009; **250**: 738-746 [PMID: 19801927 DOI: 10.1097/SLA.0b013e3181bd582b]

16 **Maggs JR**, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2012; **35**: 1113-1134 [PMID: 22432733 DOI: 10.1111/j.1365-2036.2012.05072.x]

17 **Lee PH**, Lin WJ, Tsang YM, Hu RH, Sheu JC, Lai MY, Hsu HC, May W, Lee CS. Clinical management of recurrent hepatocellular carcinoma. *Ann Surg* 1995; **222**: 670-676 [PMID: 7487215]

18 **Ho CM**, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. *Surgery* 2012; **151**: 700-709 [PMID: 22284764 DOI: 10.1016/j.surg.2011.12.015]

19 **Chan AC**, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST, Lo CM. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? *Liver Transpl* 2013; **19**: 411-419 [PMID: 23447460 DOI: 10.1002/lt.23605]

21 **Chan DL**, Morris DL, Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - a systematic review. *Surg Oncol* 2013; **22**: e23-e30 [PMID: 23535302 DOI: 10.1016/j.suronc.2013.02.009]

22 **Mise Y**, Hasegawa K, Shindoh J, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. The Feasibility of Third or More Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma. *Ann Surg* 2015; **262**: 347-357 [PMID: 25185473 DOI: 10.1097/SLA.0000000000000882]

23 **Belghiti J**, Cortes A, Abdalla EK, Régimbeau JM, Prakash K, Durand F, Sommacale D, Dondero F, Lesurtel M, Sauvanet A, Farges O, Kianmanesh R. Resection prior to liver transplantation for hepatocellular carcinoma. *Ann Surg* 2003; **238**: 885-92; discussion 892-3 [PMID: 14631225 DOI: 10.1097/01.sla.0000098621.74851.65]

24 **Del Gaudio M**, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F, Ramacciato G, Grazi GL, Pinna AD. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. *Am J Transplant* 2008; **8**: 1177-1185 [PMID: 18444925 DOI: 10.1111/j.1600-6143.2008.02229.x]

25 **Moon JI**, Kwon CH, Joh JW, Choi GS, Jung GO, Kim JM, Shin M, Choi SJ, Kim SJ, Lee SK. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival. *Transplant Proc* 2012; **44**: 487-493 [PMID: 22410053 DOI: 10.1016/j.transproceed.2011.11.009]

26 **Hwang S**, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ, Ha TY, Song GW. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. *Liver Transpl* 2007; **13**: 741-746 [PMID: 17457860 DOI: 10.1002/lt.21157]

27 **Liu F**, Wei Y, Wang W, Chen K, Yan L, Wen T, Zhao J, Xu M, Li B. Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection. *PLoS One* 2012; **7**: e48932 [PMID: 23145027 DOI: 10.1371/journal.pone.0048932]

28 **Kaido T**, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T, Yagi S, Uemoto S. Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection. *Surgery* 2012; **151**: 55-60 [PMID: 21943635 DOI: 10.1016/j.surg.2011.06.032]

29 **Adam R**, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? *Ann Surg* 2003; **238**: 508-18; discussion 518-9 [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44]

30 **Chan DL**, Alzahrani NA, Morris DL, Chua TC. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 31-41 [PMID: 24117517 DOI: 10.1111/jgh.12399]

31 **Tuci F**, Vitale A, D'Amico F, Gringeri E, Neri D, Zanus G, Bassi D, Polacco M, Boetto R, Lodo E, Germani G, Burra P, Angeli P, Cillo U. Survival benefit of transplantation for recurrence of hepatocellular carcinoma after liver resection. *Transplant Proc* 2014; **46**: 2287-2289 [PMID: 25242770 DOI: 10.1016/j.transproceed.2014.07.031]

32 **Fuks D**, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. *Hepatology* 2012; **55**: 132-140 [PMID: 21932387 DOI: 10.1002/hep.24680]

33 **Margarit C**, Escartín A, Castells L, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. *Liver Transpl* 2005; **11**: 1242-1251 [PMID: 16184539 DOI: 10.1002/lt.20398]

34 **Tribillon E**, Barbier L, Goumard C, Irtan S, Perdigao-Cotta F, Durand F, Paradis V, Belghiti J, Scatton O, Soubrane O. When Should We Propose Liver Transplant After Resection of Hepatocellular Carcinoma? A Comparison of Salvage and De Principe Strategies. *J Gastrointest Surg* 2016; **20**: 66-76; discussion 76 [PMID: 26582597 DOI: 10.1007/s11605-015-3018-6]

35 **Agopian VG**, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. *J Am Coll Surg* 2015; **220**: 416-427 [PMID: 25690672 DOI: 10.1016/j.jamcollsurg.2014.12.025]

36 **Hameed B**, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level & gt; 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. *Liver Transpl* 2014; **20**: 945-951 [PMID: 24797281 DOI: 10.1002/lt.23904]

37 **Duvoux C**, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. *Gastroenterology* 2012; **143**: 986-94.e3; quiz e14-5 [PMID: 22750200 DOI: 10.1053/j.gastro.2012.05.052]

38 **Arii S**, Monden K, Niwano M, Furutani M, Mori A, Mizumoto M, Imamura M. Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. *J Hepatobiliary Pancreat Surg* 1998; **5**: 86-92 [PMID: 9683759]

39 **Cha C**, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. *J Am Coll Surg* 2003; **197**: 753-758 [PMID: 14585409 DOI: 10.1016/j.jamcollsurg.2003.07.003]

40 **Arii S**, Teramoto K, Kawamura T, Okamoto H, Kaido T, Mori A, Imamura M. Characteristics of recurrent hepatocellular carcinoma in Japan and our surgical experience. *J Hepatobiliary Pancreat Surg* 2001; **8**: 397-403 [PMID: 11702247 DOI: 10.1007/s005340100000]

41 **Poon RT**, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. *Cancer* 2000; **89**: 500-507 [PMID: 10931448]

42 **Imamura H**, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. *J Hepatol* 2003; **38**: 200-207 [PMID: 12547409 DOI: 10.1016/S0168-8278(02)00360-4]

43 **Cheng Z**, Yang P, Qu S, Zhou J, Yang J, Yang X, Xia Y, Li J, Wang K, Yan Z, Wu D, Zhang B, Hüser N, Shen F. Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection. *HPB* (Oxford) 2015; **17**: 422-427 [PMID: 25421805 DOI: 10.1111/hpb.12367]

44 **Jeng KS**, Sheen IS, Tsai YC. Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection? *Am J Gastroenterol* 2004; **99**: 1503-1509 [PMID: 15307868 DOI: 10.1111/j.1572-0241.2004.30227.x]

45 **Wu JC**, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. *J Hepatol* 2009; **51**: 890-897 [PMID: 19747749 DOI: 10.1016/j.jhep.2009.07.009]

46 **Fan ST**, Poon RT, Yeung C, Lam CM, Lo CM, Yuen WK, Ng KK, Liu CL, Chan SC. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. *Br J Surg* 2011; **98**: 1292-1300 [PMID: 21656513 DOI: 10.1002/bjs.7583]

47 **Pompili M**, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, Brunello F, Pinna AD, Giorgio A, Giulini SM, De Sio I, Torzilli G, Fornari F, Capussotti L, Guglielmi A, Piscaglia F, Aldrighetti L, Caturelli E, Calise F, Nuzzo G, Rapaccini GL, Giuliante F. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. *J Hepatol* 2013; **59**: 89-97 [PMID: 23523578 DOI: 10.1016/j.jhep.2013.03.009]

48 **Mathews P**, Lee D, Chung YH, Kim JA, Lee JH, Jin YJ, Park W, Lyu H, Jaffee E, Zheng L, Yu E, Lee YJ. Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinoma. *Ann Surg Oncol* 2013; **20**: 1216-1222 [PMID: 23104706 DOI: 10.1245/s10434-012-2706-7]

49 **Hung IF**, Wong DK, Poon RT, Fong DY, Chui AH, Seto WK, Fung JY, Chan AC, Yuen JC, Tiu R, Choi O, Lai CL, Yuen MF. Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. *PLoS One* 2016; **11**: e0148493 [PMID: 26901762 DOI: 10.1371/journal.pone.0148493]

50 **Johnson PJ**. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. *Clin Liver Dis* 2001; **5**: 145-159 [PMID: 11218912 DOI: 10.1016/S1089-3261(05)70158-6]

51 **Ho CM**, Wu CY, Lee PH, Lai HS, Ho MC, Wu YM, Hu RH. Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma. *Ann Surg Oncol* 2013; **20**: 2526-2533 [PMID: 23504121 DOI: 10.1245/s10434-013-2940-7]

52 **Nanashima A**, Taura N, Abo T, Ichikawa T, Sakamoto I, Nagayasu T, Nakao K. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. *Dig Dis Sci* 2011; **56**: 3086-3100 [PMID: 21706206 DOI: 10.1007/s10620-011-1796-6]

53 **Zhang XF**, Qi X, Meng B, Liu C, Yu L, Wang B, Lv Y. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. *Eur J Surg Oncol* 2010; **36**: 718-724 [PMID: 20538423 DOI: 10.1016/j.ejso.2010.05.022]

54 **Tangkijvanich P**, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. *J Clin Gastroenterol* 2000; **31**: 302-308 [PMID: 11129271 DOI: 10.1097/00004836-200012000-00007]

55 **Santambrogio R**, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S. Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. *Ann Surg Oncol* 2012; **19**: 426-434 [PMID: 21732145 DOI: 10.1245/s10434-011-1845-6]

56 **Yamamoto K**, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. *Ann Surg Oncol* 2009; **16**: 2795-2804 [PMID: 19669841 DOI: 10.1245/s10434-009-0618-y]

57 **Yang SL**, Liu LP, Yang S, Liu L, Ren JW, Fang X, Chen GG1, Lai PB. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. *Br J Surg* 2016; Epub ahead of print [PMID: 26996727 DOI: 10.1002/bjs.10093]

58 **Ma WJ**, Wang HY, Teng LS. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. *World J Surg Oncol* 2013; **11**: 212 [PMID: 23981851 DOI: 10.1186/1477-7819-11-212]

59 **Shim JH**, Yoon DL, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. *Ann Surg Oncol* 2012; **19**: 3687-3696 [PMID: 22644512 DOI: 10.1245/s10434-012-2416-1]

60 **Sterling RK**, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. *Am J Gastroenterol* 2012; **107**: 64-74 [PMID: 21931376 DOI: 10.1038/ajg.2011.312]

61 **Pang RW**, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. *Ann Surg Oncol* 2008; **15**: 962-971 [PMID: 18236113 DOI: 10.1245/s10434-007-9730-z]

62 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

63 **Rodríguez-Perálvarez M**, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. *Ann Surg Oncol* 2013; **20**: 325-339 [PMID: 23149850 DOI: 10.1245/s10434-012-2513-1]

64 **Sumie S**, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, Kojiro M, Sata M. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. *Ann Surg Oncol* 2008; **15**: 1375-1382 [PMID: 18324443 DOI: 10.1245/s10434-008-9846-9]

65 **Villanueva A**, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 1501-12.e2 [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006]

66 **Roayaie S**, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. *Gastroenterology* 2009; **137**: 850-855 [PMID: 19524573 DOI: 10.1053/j.gastro.2009.06.003]

67 **Shah SA**, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. *Surgery* 2007; **141**: 330-339 [PMID: 17349844 DOI: 10.1016/j.surg.2006.06.028]

68 **Lee SY**, Konstantinidis IT, Eaton AA, Gönen M, Kingham TP, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR. Predicting recurrence patterns after resection of hepatocellular cancer. *HPB* (Oxford) 2014; **16**: 943-953 [PMID: 25041404 DOI: 10.1111/hpb.12311]

69 **Grazi GL**, Cescon M, Ravaioli M, Ercolani G, Gardini A, Del Gaudio M, Vetrone G, Cavallari A. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. *Aliment Pharmacol Ther* 2003; **17** Suppl 2: 119-129 [PMID: 12786623]

70 **Taura K**, Ikai I, Hatano E, Yasuchika K, Nakajima A, Tada M, Seo S, Machimoto T, Uemoto S. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. *Surgery* 2007; **142**: 685-694 [PMID: 17981188 DOI: 10.1016/j.surg.2007.05.009]

71 **Beard RE**, Hanto DW, Gautam S, Miksad RA. A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. *Surgery* 2013; **154**: 545-555 [PMID: 23777589 DOI: 10.1016/j.surg.2013.02.019]

72 **Hung IF**, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. *Am J Gastroenterol* 2008; **103**: 1663-1673 [PMID: 18616655 DOI: 10.1111/j.1572-0241.2008.01872.x]

73 **Takenaka K**, Yamamoto K, Taketomi A, Itasaka H, Adachi E, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. *Hepatology* 1995; **22**: 20-24 [PMID: 7601413]

74 **Kao WY**, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. *World J Surg* 2011; **35**: 858-867 [PMID: 21207029 DOI: 10.1007/s00268-010-0928-z]

75 **Utsunomiya T**, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T, Kokudo N. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. *Ann Surg* 2015; **261**: 513-520 [PMID: 25072437 DOI: 10.1097/SLA.0000000000000821]

76 **Pan QX**, Zhang JH, Su ZJ, Wang CR, Ke SY. The Glasgow Prognostic Score is an independent prognostic predictor of hepatocellular carcinoma following radical resection. *Oncol Res Treat* 2014; **37**: 192-197 [PMID: 24732643 DOI: 10.1159/000361082]

77 **Forrest LM**, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Br J Cancer* 2003; **89**: 1028-1030 [PMID: 12966420 DOI: 10.1038/sj.bjc.6601242]

**P-Reviewer:** Sipos F **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Table 1 Comparison between prophylactic liver transplant and wait-and-see before HCC recurrence**

|  |  |  |
| --- | --- | --- |
| **The strategy** | **Prophylactic LT** | **Wait-and-see** |
| Immunosuppressant exposure | Life-long | Nil |
| Surgical morbidity and mortality | Present | Nil |
| Long-term HCC recurrence | Lower[32] | Higher[11] |
| Survival benefit  (5-year survival rate) | 84.6%[32] | Around 70%[7-10] |
| Further management after recurrence | Hepatectomy, RFA, TACE, Sorafenib, Yttrium-90 | SLT, repeat hepatectomy, RFA, TACE, Sorafenib, Yttrium-90 |

LT: Liver transplant; RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization.

**Table 2 Prognostic factors of early hepatocellular carcinoma recurrence after liver resection and after liver transplantation**

|  |  |  |
| --- | --- | --- |
| **Risk factor of HCC recurrence** | **After liver resection** | **After liver transplantation** |
| Serological |  |  |
| AFP | > 400 ng/mL[49] | > 1000 ng/mL[34,35] |
| Tumor Gross |  |  |
| Tumor size | > 3 cm[30] or > 5 cm[37,41,65] | > 6 cm[35] |
| Tumor number | > 3[65] | ≥ 4[35] |
| Satellite nodules | Yes[30,63,66] | Yes[33] |
| Tumor Microscopic |  |  |
| Tumor differentiation | Intermediate, or poor differentiation, or undifferentiation[30,49,65] | Poor differentiation, or undifferentiation[33] |
| Microvascular invasion | Yes[30,37,41,49,64,65,66] | Yes[33,34] |
| Liver parenchyma |  |  |
| Severity of cirrhosis | Controversial[67-69] | No |
| Milan criteria | Yes[68] (predict recurrence within/beyond MC) | Yes[3] |

**Table 3 Scoring systems for predicting hepatocellular carcinoma recurrence. Higher scores indicate higher recurrence rate**

|  |  |  |  |
| --- | --- | --- | --- |
| **Author** | **Basis of scoring system** | **Prognostic factors** | **Discriminated Scores** |
| Pan *et al*[74] | Glasgow prognostic score | Preoperative  CRP > 10 mg/L (1 point)  Albumin < 3.5 g/L (1 point) | 0,1,2 |
| Fuks *et al*[30] | Histological features | Microscopic vascular invasion  Presence of satellite nodules  Tumor size > 3 cm  Poor differentiated tumor  Cirrhosis | < 3 factors  ≥ 3 factors |
| Roayaie *et al*[64] | Degree of vascular invasion | Invasion of a vessel with a muscular wall (1 point)  Invasion of a vessel ≥ 1 cm from the tumor capsule (1 point) | 0,1,2 |
| Lee *et al*[66] | Clinical risk score | Initial disease beyond Milan criteria  Microsatellites or multiple tumors  Lymphovascular invasion  (1 point for each factor) | 0,1,2,3 |